aot2022v55i1

More documents

Recommendations

Info

Acta Oncologica Turcica 2022EDITORIAL BOARDOwnerOn behalf of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalProf. Fevzi ALTUNTAŞ, MD (Chief Physician)Yildirim Beyazit University School of Medicine, Department of Hematology, Ankara, TurkeyEditor in ChiefProf. Ömür Berna ÇAKMAK ÖKSÜZOĞLU, MDUniversity of Health Sciences Gülhane Medical School, Department of Internal Medicine, Ankara, TurkeyAssociate EditorProf. Cihangir ÖZASLAN, MDUniversity of Health Sciences Gülhane Medical School, Department of General Surgery, Ankara, TurkeySection EditorsProf. Süheyla ÜNVER, MDDr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Anesthesiologyand Reanimation, Ankara, TurkeyAssoc. Prof. Mehmet Sinan DAL, MDUniversity of Health Sciences Gülhane Medical School, Department of Internal Medicine, Ankara, TurkeyProf. Mutlu DOĞAN, MDDr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology,Ankara, TurkeyAssoc. Prof. Taha BAHSİ, MDDr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Genetics,Ankara, TurkeyAssoc. Prof. Recep ÖZTÜRK, MDDr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Orthopedics andTraumatology, Ankara, TurkeyAssoc. Prof. Burcu SAVRAN, MDDr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Radiology, Ankara,TurkeySemih BAŞÇI, MDDr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Hematology,Ankara, TurkeyPublishing CoordinatorAssoc. Prof. Haktan Bağış ERDEM, MDDr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Genetics,Ankara, Turkeywww.actaoncologicaturcica.comCopyright©Ankara Onkoloji Hastanesi
Acta Oncologica Turcica 20221INSTRUCTION TO THE AUTHORSThe manuscripts regarding with hematological malignancies and oncology, written inEnglish will be accepted to the Acta Oncologica Turcica, which is the scientific journal ofUniversity of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training andResearch Hospital.The abbreviation of the Acta OncologicaTurcica is “Acta Oncol Tur.”.Manuscripts that are not compatible with the journal format are sent back to thecorresponding author without reviewer assignment.During submission, all manuscripts should be checked primarily for plagiarism rate andgrammatical rules. Except for the references section, the plagiarism rate should be below20%. The author is responsible for obtaining the plagiarism report and the accuracy of thereport obtained.The scientific and the legal responsibilities belong to the authors. The copyrights of thepublications belong to the Acta Oncologica Turcica. The authors are responsible for thecontent of the papers and for the accuracy of the references.The authors must submit 'Copyright Transfer Form' during the submission of manuscript. Bysigning the 'Copyright Transfer Form' the authors guarantee the fact that the article has notbeen published nor under consideration for publication in whole or in part, elsewhere. Theauthors attest to the fact that they all have read the manuscript, attest to the validity andlegitimacy of the data and its interpretation, and agree to its submission to the ActaOncologica Turcica.All research articles should be conducted in accordance with the Helsinki Declaration(revisedin 2013) and manuscripts should include a statement that the research protocol wasapproved by the Institutional Ethical Committee or equivalent. Both the 'InformedConsent' and approval from ethical committee should be described in the 'Materials andMethods' section of the manuscript.For peer-review process, a blind manuscript should be prepared by the author and submittedto the system as a separate file.For the experimental animal studies, the authors must include a statement that they protect theanimal rights according to the "Guide for the care and use of laboratory animals"( http://oacu.od.nih.gov/regs/guide/guide.pdf) and must obtain approval from InstitutionalEthical Committee.All sources of funds supporting the work and a statement of financial interest, if any, must beincluded, along with a list of all products, devices, drugs, etc., used in the manuscript. Eachauthor must disclose at the time of submission any commercial associations or financialdisclosures that might pose or create a conflict of interest. Such associations includeconsultancies, stock ownership, or other equity interests, and payments for conducting a studydescribed in the manuscript. Authors must disclose any funding received for the work fromwww.actaoncologicaturcica.comCopyright©Ankara Onkoloji Hastanesi
Page 4 and 5: Acta Oncologica Turcica 20222any or
Page 6 and 7: Acta Oncologica Turcica 20224KEYWOR
Page 8 and 9: Acta Oncologica Turcica 20226found
Page 10 and 11: Value of ADC Thresholds to Diagnose
Page 12 and 13: Acta Oncologica Turcica 2022; 55: 1
Page 52 and 53:
Acta Oncologica Turcica 2022; 55: 3
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86:
show all

aot2022v55i1

Create successful ePaper yourself

Delete template?

Save as template?